{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.97","upperLimit":"3.35","value":"2.48"},{"groupId":"OG001","lowerLimit":"2.19","upperLimit":"2.93","value":"2.55"},{"groupId":"OG002","lowerLimit":"1.61","upperLimit":"3.16","value":"2.37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"29"}],"units":"Participants"}],"description":"Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received cyclophosphamide during consolidation cycle 2 and had samples collected for PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion","title":"Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 2","type":"SECONDARY","unitOfMeasure":"L/h/m^2"}